Physician profile
Robert G Sperry
NPI 1417045550
$2,176.52
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $403 · 2021: $16.51 · 2022: $23.50 · 2023: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $375.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $277.08 | 2019-2020 | |
| Pfizer INC. | $222.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $200.53 | 2019-2020 | |
| Amgen INC. | $179.44 | 2019-2021 | |
| Novo Nordisk INC | $178.18 | 2019-2020 | |
| Lilly USA, LLC | $137.08 | 2019 | |
| Medtronic, INC. | $101.75 | 2023 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.84 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $71.41 | 2019 | |
| Abbott Laboratories | $47.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $40.33 | 2019 | |
| Glaxosmithkline, LLC. | $33.18 | 2019 | |
| Allergan, INC. | $31.44 | 2019 | |
| Bioventus LLC | $30.18 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $23.70 | 2019 | |
| Merck Sharp & Dohme LLC | $22.09 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2019 | |
| Astellas Pharma US INC | $18.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.91 | 2019 | |
| Horizon Therapeutics Plc | $13.34 | 2020 | |
| Boston Scientific Corporation | $11.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.